Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ON Holding AG (ONON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ON Holding AG — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while ON Holding AG trades at $35.83 (market cap $12.21B). The key difference: ON Holding AG is far larger — about 2.7× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| ACAD | ONON | |
|---|---|---|
Market Cap | $4.49B | $12.21B |
Sector | Health | Technology |
52-Week High | $28.06 | $54.24 |
52-Week Low | $20.06 | $31.88 |
Enterprise Value | $3.69B | $11.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ONON trades at $36.87, up 0.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 63.88% gross margin and 15.5% ROE, supported by revenue growth to $3.01B in 2025. Analyst consensus is bullish with a $47.33 price target, though technical indicators suggest near-term resistance.
The outlook remains positive given consistent earnings outperformance and raised profit guidance, but risks include tariff concerns and competitive pressures. Upside potential exists if the company maintains its innovation-led growth, particularly in Asia-Pacific markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
